Expanded Access to NanoPac
Primary Purpose
Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Sponsored by

About this trial
This is an expanded access trial
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT03756311
First Posted
November 26, 2018
Last Updated
April 7, 2022
Sponsor
NanOlogy, LLC
Collaborators
US Biotest, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT03756311
Brief Title
Expanded Access to NanoPac
Official Title
Expanded Access to NanoPac
Study Type
Expanded Access
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NanOlogy, LLC
Collaborators
US Biotest, Inc.
4. Oversight
5. Study Description
Brief Summary
NanOlogy may consider offering expanded access to NanoPac for patients who do not meet the enrollment criteria of clinical trials in progress.
6. Conditions and Keywords
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Other Intervention Name(s)
Paclitaxel
10. Eligibility
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gere diZerega, MD
Phone
805-595-1300
Email
gere.dizerega@usbiotest.com
12. IPD Sharing Statement
Learn more about this trial
Expanded Access to NanoPac
We'll reach out to this number within 24 hrs